Funding the Future of
Pandemic Defense with Oral Antibody Tech
SAIZ is a blockchain-backed token that directly finances the commercialization of oral antibody treatments for rotavirus — backed by a real licensing agreement between BioLumen and LOA BIO PHARM, one of the world's leading antibody manufacturers.
Pandemics Are Inevitable. The World Isn't Ready.
Climate change, global travel, and human-animal interaction are accelerating the emergence of new viral threats. The WHO has declared only three official pandemics since 1948 — each more devastating than the last. The next one is a matter of when, not if.
Rotavirus Kills 440,000 Children a Year
Despite existing vaccines, rotavirus remains the leading cause of fatal diarrhoeal disease in children under five. Most deaths occur in South Asia and sub-Saharan Africa, where treatment is unaffordable and access is limited.
440,000 deaths/yearAvian Flu — A Pandemic Waiting to Happen
H5N1 Avian Influenza has a confirmed human fatality rate exceeding 50%. As spillover events from birds to humans increase globally, health agencies classify it among the highest-priority pandemic threats.
>50% human fatality rate80% of New Diseases Are Zoonotic
COVID-19 brought zoonotic disease into sharp global focus. Approximately 80% of all emerging infectious diseases originate from animals — and accelerating deforestation and urbanization are making future outbreaks more, not less, likely.
80% of emerging infectionsExisting Solutions Are Out of Reach
Today's treatments — injectable vaccines and antivirals — require cold-chain logistics, medical personnel, and significant cost. This creates a massive affordability and access gap in exactly the regions most at risk.
Access & cost barriersThree Official WHO Pandemics Since 1948
In over 75 years, the WHO has declared only three global pandemics — each reshaping public health, economies, and societies permanently. The acceleration of viral threats means we cannot afford to wait for the next one to act.
Hong Kong Flu (H3N2)
An H3N2 influenza pandemic that caused an estimated 1–4 million deaths worldwide and triggered the first modern pandemic preparedness frameworks.
Swine Flu (H1N1)
Spread to 214 countries within months, infecting hundreds of millions. Estimated 151,000–575,000 deaths in the first year alone.
COVID-19
The most disruptive pandemic in a century — over 7 million confirmed deaths, trillions in economic damage, and a permanent reset of global health priorities.
80% of New Infectious Diseases Are Zoonotic
COVID-19 is widely believed to have spread to humans via an intermediate animal host. As human activity continues to encroach on wildlife habitats, zoonotic spillover events will become more frequent — making oral, deployable antibody solutions critical.
Oral Antibodies — A Simpler, Faster Way to Fight Pandemics
SAIZ finances the commercialization of oral antibody technology through a formal licensing partnership between BioLumen and LOA BIO PHARM — enabling treatment without injections, cold chains, or specialized infrastructure.
💊No Needles. No Cold Chain.
Oral antibodies are ingested, not injected. OMR's globally unrivaled IgY technology produces thermostable antibodies that retain full effectiveness in the digestive tract — dramatically reducing the cost and complexity of mass deployment.
📜Rotavirus Asian License Rights
SAIZ is powered by a licensing agreement between BioLumen and LOA BIO PHARM for a standardized rotavirus oral antibody across Korea, Thailand, and India. Royalties from commercial sales flow directly into the SAIZ ecosystem — creating a real, recurring revenue foundation.
🇮🇳Primary Markets — Korea, Thailand, & India
Targeting high-growth healthcare markets across Korea, Thailand, and India. With a combined population of over 1.5 billion and significant rotavirus burdens, these regions represent the immediate commercial priority for SAIZ’s licensed antibody products.
🌐LOA BIO PHARM — Global Raw Material Supplier
LOA BIO PHARM is a worldwide supplier of high-purity antibody raw materials. Their ceramic IgY production technology provides the critical scientific foundation and raw material security for the entire SAIZ ecosystem.
Global Raw Material Supplier
Token Economics & Real-World Utility
SAIZ is a CNX-20 utility token with a hard-capped 50 million supply, real royalty revenue backing, staking rewards, and a live payment utility through the Copay card.
Total Supply
50,000,000
SAIZ Tokens — Fixed, Non-Inflationary
Hard-Capped at 50 Million
SAIZ has a fixed, non-inflationary total supply of 50,000,000 tokens. No additional tokens can ever be minted, ensuring scarcity is built in from day one — giving every holder permanent, proportional ownership of the ecosystem.
Royalty-Funded Staking Rewards
Token holders earn staking rewards funded directly by royalties from the BioLumen & LOA BIO PHARM licensing agreement. This is not yield conjured from token inflation — it's real revenue from a real product being sold in real markets.
Copay Card — Spend SAIZ Anywhere
The Copay card integrates with the SAIZ wallet, allowing holders to spend their tokens at any Copay-network merchant. This provides real, immediate utility beyond trading — positioning SAIZ as a functional currency, not just a speculative asset.
On-Chain Governance Rights
SAIZ holders vote on major project decisions — partner approvals, exchange listings, treasury deployments, and ecosystem direction. Governance transitions to full DAO model in 2027, with the SAIZ Foundation established as an independent oversight entity.
One Token. Four Pillars of Value.
SAIZ isn't just a token — it's an ecosystem connecting world-class antibody technology, blockchain infrastructure, global education, and real-world payments into a single, unified value network.
Cofinex.io — Blockchain & Exchange
SAIZ is built on the Cofinex blockchain as a native CNX-20 token, and listed on Cofinex.io — a Global & India-based exchange strategically aligned with SAIZ's primary commercial markets in Korea, Thailand, and India. TGE listing price: $1.50 per token.
Copay Card — Real-World Payments
The Copay card enables SAIZ holders to spend tokens as a payment method in everyday life — creating organic demand, token velocity, and real-world utility far beyond the trading desk.
Happy Blockchain Academy (HBA)
HBA is SAIZ's global blockchain education network, operating across Asia with expansion targets in Africa, South America, and Europe. HBA communities serve as ambassadors and user acquisition channels — turning education into ecosystem growth.
Progressive DAO Governance
Governance is progressively handed to the community. By 2027, full on-chain DAO governance will be live, with the SAIZ Foundation established as an independent non-profit to oversee the ecosystem.
Primary Exchange Listing
cofinex.io
SAIZ is listed on Cofinex.io — an Global & India-based exchange aligned with our primary market. TGE listing price: $1.50 per token. Future listings target additional Asian and Tier-1 global exchanges.
Trade on Cofinex.io →Four Phases. One Mission.
The SAIZ project roadmap runs from 2025 to 2028 across four progressive phases — each building on the last to accelerate both the oral antibody commercialization and the growth of the SAIZ token ecosystem.
Foundation & Token Launch
Token Generation Event (TGE) on Cofinex.io. BioLumen & LOA BIO PHARM licensing agreement finalized. Core governance framework designed and audited. SAIZ listed at $0.97/token.
India Market Entry
Begin CDSCO regulatory submissions for rotavirus antibody product in India. Copay card integration launched. HBA expansion across Asia. Initial royalty revenue generation.
Ecosystem Expansion
Second major exchange listing (Asian or global). On-chain governance platform launched with live community votes. Indian pharmaceutical partnerships signed.
Global Scale & Full DAO
Tier-1 global exchange listing. Full DAO governance live. SAIZ Foundation established. Southeast Asian healthcare distributor partnerships. HBA expansion to 20+ countries.
Timelines reflect realistic execution based on current partnership status and regulatory requirements. All forward-looking statements are subject to risk.
Be Part of the Pandemic Prevention Revolution
SAIZ gives you a stake in a mission that matters — oral antibody technology that could protect millions, backed by a real licensing deal, real revenue, and a community-governed blockchain ecosystem.